Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 - Q3 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/06/25	19.00 $	+23.62%	516,812
11/06/25	15.37 $	+5.64%	217,906
10/06/25	14.55 $	-4.34%	305,626
09/06/25	15.21 $	-1.55%	154,935
06/06/25	15.45 $	+12.36%	199,613

Delayed Quote Nasdaq, June 12, 2025 at 11:00 pm

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 23:00:00 12/06/2025 +03			5-day change	1st Jan Change
19.00 ^USD	+23.62%		+30.76%	+416.30%

06-10	Quantum Biopharma Purchases More Bitcoin Bringing Total Investment In Digital Assets To USD $5,000,000	RE
06-10	Quantum BioPharma Down 1.4% In US Premarket As Purchases More Bitcoin, Bringing Total Investment in Digital Assets to US$5 Million	MT

Capitalization	58.14M 42.75M 36.87M 34.62M 31.39M 3.66B 65.45M 403M 157M 1.68B 160M 157M 6.13B	P/E ratio 2023	-2.01x	P/E ratio 2024	-0.29x
Enterprise value	51.77M 38.06M 32.83M 30.82M 27.95M 3.25B 58.28M 359M 140M 1.5B 143M 140M 5.46B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	72%	Yield 2023 *	-	Yield 2024	-

Quantum Biopharma Purchases More Bitcoin Bringing Total Investment In Digital Assets To USD $5,000,000	06-10	RE
Quantum BioPharma Down 1.4% In US Premarket As Purchases More Bitcoin, Bringing Total Investment in Digital Assets to US$5 Million	06-10	MT
Quantum Biopharma Brief: Says Purchased More Bitcoin (BTC) Bringing Total Investment in Digital Assets to US$5 Million	06-10	MT
INGENu CRO Partners with Quantum Biopharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients	06-02	CI
Quantum Biopharma Receives US$2.35 Million From Legal Settlement With Raza Bokhari	05-30	MT
Quantum Biopharma Brief: Says Received US$2.35 Million From a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari	05-30	MT
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP	05-29	RE
Quantum Biopharma Ltd. Receives Ethics Committee Approval for Phase 2 Clinical Trial of Fsd202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome	05-28	CI
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202	05-28	RE
Quantum BioPharma Receives Australian Ethics Committee Approval for Phase 2 FSD202 Trial	05-28	MT
Quantum Biopharma Chooses BitGo to Store Cryptocurrency Holdings	05-21	MT
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS)	05-20	CI
Quantum Biopharma Seals Deal With Contract Research Organization for Lucid-MS Application	05-20	MT

Quantum Biopharma Purchases More Bitcoin Bringing the Total Investment in Digital Assets to USD $5,000,000	06-11	AQ
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000	06-10	GL
Quantum BioPharma Clarifies It Has Not Changed Its Name	06-03	GL
Quantum BioPharma Clarifies It Has Not Changed Its Name	06-03	AQ
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari	05-30	GL

Quantum BioPharma Ltd. Stock Nasdaq

Equities

QNTM

CA74764Y2050

Biotechnology & Medical Research

Valuation: Quantum BioPharma Ltd.

Chart: Quantum BioPharma Ltd.

Latest news: Quantum BioPharma Ltd.

Press Releases: Quantum BioPharma Ltd.

News in other languages: Quantum BioPharma Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Quantum BioPharma Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Tesla retira de mercado EEUU unos 362.000 autos por problemas en software de conducción autónoma	16/02/23
IRW-PRESS : FSD Pharma Inc.: FSD Pharma gibt -2-	25/08/21
IRW-PRESS : FSD Pharma Inc.: FSD Pharma gibt endgültige Vereinbarung zur Übernahme von Lucid Psycheceuticals bekannt	25/08/21
IRW-News: FSD Pharma Inc.: Gericht ordnet an, dass FSD Pharma den Termin der Aktionärsversammlung auf den 14. Mai 2021 verlegt, ein unabhängiger Versammlungsleiter bestellt wird und Dr. Raza Bokhari sowie weiteren Direktoren das Stimmrecht für neu ausgegebene Aktien entzogen wird	08/03/21
IRW-PRESS : FSD Pharma Inc.: Gericht ordnet an, -2-	08/03/21

1 day	+23.62%
1 week	+30.76%
Current month	+41.16%
1 month	+109.37%
3 months	+313.94%
6 months	+346.01%
Current year	+416.30%

1 week	12.75	19.32
1 month	7.96	19.32
Current year	2.89	19.32
1 year	2.7	23.81
3 years	2.7	136.5
5 years	2.7	446.55
10 years	2.7	11,431.95

Manager	Title	Age	Since
Zeeshan Saeed CEO	Chief Executive Officer	55	04/07/2023
Donal Carroll DFI	Director of Finance/CFO	49	30/08/2024
Andrzej Chruscinski CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Anthony Durkacz CHM	Chairman	49	14/05/2021
Zeeshan Saeed CHM	Chairman	55	14/05/2021
Adnan Bashir BRD	Director/Board Member	55	01/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
QUANTUM BIOPHARMA LTD.	+23.62%	+30.76%	-	-	46.78M
REGENERON PHARMACEUTICALS, INC.	+0.62%	+7.61%	-48.36%	-8.74%	54.8B
ARGENX SE	-0.12%	-0.43%	+43.82%	+61.96%	35.51B
BEONE MEDICINES LTD.	+5.38%	+7.07%	+74.37%	+87.52%	33.43B
WUXI APPTEC CO., LTD.	+4.09%	+3.98%	+59.47%	-34.15%	26.04B
BIONTECH SE	-0.51%	-5.60%	+6.19%	-27.06%	25.35B
INSMED INCORPORATED	-1.12%	+31.47%	+56.59%	+430.27%	17.85B
SUMMIT THERAPEUTICS INC.	+2.96%	+3.07%	+167.37%	+2,004.38%	14.54B
GENMAB A/S	-0.03%	+3.16%	-21.65%	-28.17%	14.08B
WUXI BIOLOGICS (CAYMAN) INC.	+4.13%	+10.12%	+152.73%	-59.78%	13.81B
Average	+3.90%	+5.66%	+54.50%	+269.58%	26.16B
Weighted average by Cap.	+1.63%	+4.92%	+35.45%	+164.28%

	2023	2024
Net sales	-	-
Net income	-17.9M -13.16M -11.35M -10.66M -9.67M -1.13B -20.15M -124M -48.37M -519M -49.37M -48.33M -1.89B	-14.2M -10.44M -9.01M -8.46M -7.67M -893M -15.99M -98.52M -38.37M -411M -39.17M -38.34M -1.5B
Net Debt	-3.17M -2.33M -2.01M -1.89M -1.71M -200M -3.57M -22.02M -8.58M -91.95M -8.75M -8.57M -335M	-6.37M -4.69M -4.04M -3.79M -3.44M -401M -7.18M -44.21M -17.22M -185M -17.58M -17.21M -672M